Skip to Content

Non-Medical Switches of Biosimilar in Psoriasis Treatment Appears Safe

Christoffer Willy Schwarz presented a real-world study at EADV 2024 on non-medical switches between adalimumab products in psoriasis patients. Among 180 patients, the risk of discontinuation within six months was 0-8%, with the highest rate (8%) linked to switching from the reference drug to a biosimilar. The results suggest switching is generally safe, although the study is limited by its size and scope.

Christopher Willy Schwarz

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top